Forward-Looking Statements Except for historical information, this report on Varian Medical Systems’ financial performance contains forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers
Slide 4: Q1 FY09 Earnings Results
Q1 FY09 Earnings Results In millions In millions Backlog 120 1950 100 + 1900 ae 1050. 900. 60 1750- 40 + 700. 400 a 1650. 600. 0 ) 41550 108 109 tos ato9 Fy2008 | FY2009 @ Orders @ Revenues Op Earnings Mi Net Earnings $1,930M (as of 01/02/09) Net Earnings per diluted share: $0.56 Note: The results e
Slide 5: Oncology Systems
Oncology Systems Products + Linear Accelerators + Accessories + Software Applications + Radiotherapy + Radiosurgery Indications + Cancer - Primary - Metastatic + Neurological conditions
Slide 6: RapidArc Update
RapidArc Update 425+ orders 70+ installs complete ~ 100 media stories Treatments underway Prostate Head & neck Sarcoma Lung Early stage metastatic disease VARJAN | Apartner forlife neulaal syeteme!
Slide 7: X-Ray Products
| x ™ X-Ray Products Flat Panel Detectors X-Ray Tubes
Slide 8: Other
Other Security and Inspection Products ACCEL Proton Therapy ae He Ginzton Technology Center VARTAN | A partner for life
Slide 9: First Quarter 2009 Results
First Quarter 2009 Results 7 Net Orders 551 13% 428 11% 91 21% 33 15% Revenues 509 13% 398 11% 86 23% 24 17% Gross Margin 43% 44% 40% 43% R&D 37 SG&A 83 Op Earnings 99 19% ROS (+13%) Interest Income 1 EPS $0.56 Cla nr a ue acne penn pa psn VARJAN meatal s voserne life
Slide 10: Q1 FY09 Balance Sheet and Cash Flow
Q1 FY09 Balance Sheet and Cash Flow Conservative balance sheet $423M cash and cash equivalent $65M total debt $1,042M stockholder equity *DSO 83 days — down 4 days from year ago quarter Strong cash flow $85M Q1 cash flow from operations Spent $72M to repurchase 1.5M shares during the quarter *Days S
Slide 11: Fiscal 2009 Outlook
Fiscal 2009 Outlook (As of end of First Quarter, Fiscal 2009) = Revenues growth estimated at 10-13% for FY 2009 : EPS estimated at ~ $2.59 to $2.64 for FY 2009 = Revenues growth estimated at ~ 9-10% for Q2 FY 2009 » EPS estimated at ~ $0.59 to $0.62 for Q2 FY 2009 Varian updates its outlook once per
Slide 12: Tim Guertin, Elisha Finney
Tim Guertin Elisha Finney President/CEO Sr. VP & CFO VARTAN A partner for life
Slide 13: Thank you
Thank you Q1 Financials aud Wetcast Mase G can be accessed at \ CC s